HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana

Bibliographic Details
Title: HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana
Authors: Kaelo Moahi, Tlotlo Ralefala, Isaac Nkele, Scott Triedman, Aliyah Sohani, Zola Musimar, Jason Efstathiou, Philipe Armand, Shahin Lockman, Scott Dryden-Peterson
Source: JCO Global Oncology, Vol , Iss 8 (2022)
Publisher Information: American Society of Clinical Oncology, 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: PURPOSEPeople living with HIV (PLWH) experience increased risk of Hodgkin lymphoma (HL) despite effective initiation of antiretroviral therapy (ART). In high-income countries, outcomes following HIV HL have been reported to be non-differential, or inferior for PLWH. We sought to assess the effect of HIV on HL survival in Botswana, an African country with a generalized HIV epidemic and high ART coverage, to describe a context more reflective of global HIV populations.PATIENTS AND METHODSIn the Thabatse Cancer Cohort, consenting participants initiating treatment for HL at one of four cancer centers in Botswana were enrolled from 2010 to 2020. Patients were followed quarterly for up to 5 years. The impact of HIV on survival following treatment initiation was assessed using an inverse probability–weighted Cox marginal structural model adjusted for age, performance status, and disease stage.RESULTSSeventy-eight new HL cases were enrolled, 47 (60%) were PLWH and 31 (40%) were HIV-uninfected. Baseline characteristics were similar between groups. The majority (61%) of patients presented with regional disease (stage I or II) with no statistically significant difference by HIV status (P = .38). Nearly all (87%) PLWH participants were on ART before their HL diagnosis (median ART duration 42 months), and median CD4 count was 413 cells/μL (interquartile range 253-691). Survival, in unadjusted analyses, was lower among patients without HIV compared with PLWH (log rank P = .021). In adjusted analysis, HIV infection was not significantly associated with survival in inverse probability–weighted Cox model (hazard ratio 0.43; 95% CI, 0.16 to 1.16; P = .094).CONCLUSIONIn this cohort of patients treated for HL in Botswana, survival in PLWH (87% on long-standing ART) was at least as good as in individuals without HIV.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2687-8941
Relation: https://doaj.org/toc/2687-8941
DOI: 10.1200/GO.21.00163
Access URL: https://doaj.org/article/7deef42da6ff4ffaa01fe170d8bcc7f7
Accession Number: edsdoj.7deef42da6ff4ffaa01fe170d8bcc7f7
Database: Directory of Open Access Journals
More Details
ISSN:26878941
DOI:10.1200/GO.21.00163
Published in:JCO Global Oncology
Language:English